Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report
Background: Anaplastic Lymphoma Kinase (ALK) inhibitors are tyrosine kinase inhibitors used as molecular-targeted therapy for non-small cell lung cancers (NSCLC) harbouring ALK translocations. Case description: This case report describes a 73-year-old female patient who was started on alectinib for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000400 |